Avak Kahvejian
Founding CEO & Board Member @ Etiome
Cambridge, United States
Avak Kahvejian is a Series B investor at Etiome in Cambridge focused on Biotechnology and Therapeutics. Avak Kahvejian is based out of Cambridge, Massachusetts, and is the General Partner of Flagship Pioneering. Avak previously worked at Sail Biomedicines as a Founding CEO and Board Member. Avak Kahvejian attended McGill University.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Avak Kahvejian invests in
Stages Avak Kahvejian invests in
Countries Avak Kahvejian invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Therapeutics 3 (43%)
- Medical 2 (29%)
- Biopharma 1 (14%)
- Health Care 1 (14%)
Stage
- Series B 3 (43%)
- Series A 2 (29%)
- Series C 1 (14%)
- Venture - Series Unknown 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Etiome
|
Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines. | $50M / Series A / Apr 24, 2025 | |
Ampersand Biomedicines
|
Ampersand Biomedicines is an Address, Navigate, Design (AND)™ Platform that develops novel programming therapeutics that are designed to act at the sight of disease. | $65M / Series B / Mar 19, 2025 | |
Ring Therapeutics
|
Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company isexpanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases. | $86.5M / Series C / Mar 09, 2023 | |
|
Ampersand Biomedicines
|
Ampersand Biomedicines is an Address, Navigate, Design (AND)™ Platform that develops novel programming therapeutics that are designed to act at the sight of disease. | $50M / Venture - Series Unknown / Mar 07, 2023 | |
Laronde
|
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidlyscaling to support the parallel development of multiple programs across many disease areas. | $440M / Series B / Aug 30, 2021 | |
|
Ring Therapeutics
|
Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company isexpanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases. | $117M / Series B / Jul 28, 2021 | |
|
Laronde
|
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidlyscaling to support the parallel development of multiple programs across many disease areas. | $50M / Series A / May 10, 2021 |
Co-Investors
About Etiome
Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.
Etiome Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Avak Kahvejian
Founding CEO & Board Member
|
|||
Noubar Afeyan
Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Avak Kahvejian invest in?
Avak Kahvejian invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Avak Kahvejian?
Public channels for Avak Kahvejian include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Avak Kahvejian last invest?
The most recent investment recorded for Avak Kahvejian closed in Apr 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
